Cargando…

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina

INTRODUCTION: Pulmonary arterial hypertension is a progressive haemodynamic disease with high morbidity and mortality. Of the different treatments available, the prostacyclin analogues are the drugs of choice for high-risk patients, with treprostinil being the most commonly used drug in Argentina. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lescano, Adrián, Giacommi, Guillermo, Botta, Cristian E., Soricetti, Julieta, Rodriguez, Manuel, Vargas Mielles, Paul, Diez, Fabián
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629562/ https://www.ncbi.nlm.nih.gov/pubmed/36314498 http://dx.doi.org/10.1177/17534666221132735

Ejemplares similares

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2018)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
por: McSweeney, Julia, et al.
Publicado: (2023)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Dosing characteristics of oral treprostinil in real-world clinical practice
por: Balasubramanian, Vijay P., et al.
Publicado: (2018)

Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
por: Kavgacı, Akif, et al.
Publicado: (2023)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Implantable system for treprostinil: a real-world patient experience study
por: Shapiro, Shelley, et al.
Publicado: (2020)

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting
por: Balasubramanian, Vijay P., et al.
Publicado: (2022)

Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension
por: Waligóra, Marcin, et al.
Publicado: (2023)

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
por: Jansa, Pavel, et al.
Publicado: (2023)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
por: Johnson, Shelsey W., et al.
Publicado: (2022)

Pediatric subcutaneous treprostinil site maintenance and pain control strategies from the Pediatric Pulmonary Hypertension Network
por: Jackson, Emma O., et al.
Publicado: (2021)

Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension
por: Mori, Ana Laura, et al.
Publicado: (2021)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
por: Desole, Susanna, et al.
Publicado: (2018)

Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin(®)) site pain: a case report
por: Brewer, Jacqueline, et al.
Publicado: (2023)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
por: Ivy, D. Dunbar, et al.
Publicado: (2019)

Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension
por: Khan, Akram, et al.
Publicado: (2022)

Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy
por: Adachi, Shiro, et al.
Publicado: (2022)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
por: Kingrey, John F., et al.
Publicado: (2023)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
por: Mirza, Shireen, et al.
Publicado: (2012)

Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review
por: Buckley, Mitchell S, et al.
Publicado: (2014)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
por: Pugliese, Steven C, et al.
Publicado: (2016)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
por: Kurzyna, Marcin, et al.
Publicado: (2017)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Developing a real-world database for oncology: a descriptive analysis of breast cancer in Argentina
por: Streich, Guillermo, et al.
Publicado: (2022)

Inhaled treprostinil: a therapeutic review
por: Channick, Richard N, et al.
Publicado: (2012)

Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension
por: Smadja, David M., et al.
Publicado: (2010)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
por: Swisher, John W., et al.
Publicado: (2016)

Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
por: Coons, James C., et al.
Publicado: (2018)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
por: Plaunt, Adam J., et al.
Publicado: (2021)

Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally
por: Behr, Jürgen
Publicado: (2021)

Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic hernia
por: De Bie, Felix Rafael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_02ti147i32q0s22afpnhbnhl4t